Skip to Content
 

News: Clinical Trials

My Cancer Genome launches new search tool for clinical trials

Friday, October 27th, 2017

My Cancer Genome (MCG), a web-based cancer information tool developed by Vanderbilt-Ingram Cancer Center investigators in 2011 and supported by GenomOncology, has launched a new clinical trial search tool that allows website visitors to search for cancer clinical trials based on disease, biomarker, phase and recruiting status.

Study to test combination therapy for breast cancer

Friday, October 27th, 2017

Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

Cancer Patient Chooses Nashville for VICC Care and the Nashville Predators

Friday, June 9th, 2017

Los Angeles native Christina Shaw had two powerful goals when she decided to move cross country to live in Nashville. The first was to support her favorite hockey team, the Nashville Predators, and the second was to meet with Leora Horn, M.D., M.Sc., a renowned lung cancer specialist at Vanderbilt-Ingram Cancer Center (VICC). Shaw, 33, […]

VICC trial putting lung cancer therapy to the test

Thursday, October 20th, 2016

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis. That head injury may have […]

New prostate cancer therapy investigated at VUMC

Thursday, September 22nd, 2016

Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation. Investigators, David Penson, M.D., MPH, professor and chair of Urologic Surgery, and Sandeep Arora, […]

Precision medicine already changing cancer treatment strategies

Thursday, May 26th, 2016

The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. “Nationwide we’re seeing great promise with this approach […]

VICC treats first patient in Tennessee with novel cellular immunotherapy

Monday, February 29th, 2016

For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. The new CAR-T investigational therapy (known as KTE-C19) is being studied in a clinical trial for patients with aggressive non-Hodgkin Lymphoma (NHL). The trial, called […]

VICC’s Horn lands Team Leadership Award from NCI

Thursday, November 19th, 2015

Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has received a 2015 Cancer Clinical Investigator Team Leadership Award (CCITLA) from the National Cancer Institute (NCI). Horn is one of 11 clinical investigators selected to receive a 2015 CCITLA, which were announced during […]

VUMC and Incyte Corp. form new scientific alliance

Thursday, October 22nd, 2015

Vanderbilt University Medical Center (VUMC) investigators have joined forces with scientists at Incyte Corp. to explore new therapies for the treatment of various types of cancer, as well as other diseases. The company has agreed to help fund basic and translational science research by VUMC investigators. Incyte Corp. is a Wilmington, Delaware-based biopharmaceutical company focused […]

Study seeks to ease ‘chemobrain’ for cancer patients

Monday, August 24th, 2015

Many women who receive chemotherapy for breast cancer report problems with their thinking, memory and attention after treatment. And as the survival rates for breast cancer increase, so do these issues associated with chemotherapy. Paul Newhouse, M.D., professor of Psychiatry and Jim Turner Professor of Cognitive Disorders, and graduate student Jennifer Vega in Vanderbilt University […]

Next Page »